The cost effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease

Patrick Gillespie; Molly Byrne

doi:10.1017/S0266462310000358

The cost effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease

Department of Economics
Department of General Practice
The Adelaide Hospital
Queen's University of Belfast

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

20 Citations (Scopus)

Abstract

Objectives: The Secondary Prevention of Heart disEase in geneRal practicE (SPHERE) trial has recently reported. This study examines the cost-effectiveness of the SPHERE intervention in both healthcare systems on the island of Ireland. Methods: Incremental cost-effectiveness analysis. A probabilistic model was developed to combine within-trial and beyond-trial impacts of treatment to estimate the lifetime costs and benefits of two secondary prevention strategies: Intervention - tailored practice and patient care plans; and Control - standardized usual care. Results: The intervention strategy resulted in mean cost savings per patient of 512.77 (95 percent confidence interval [CI], 1086.46-91.98) and an increase in mean quality-adjusted life-years (QALYs) per patient of 0.0051 (95 percent CI, 0.0101-0.0200), when compared with the control strategy. The probability of the intervention being cost-effective was 94 percent if decision makers are willing to pay €45,000 per additional QALY. Conclusions: Decision makers in both settings must determine whether the level of evidence presented is sufficient to justify the adoption of the SPHERE intervention in clinical practice.

Original language	English (Ireland)
Pages (from-to)	263-271
Number of pages	9
Journal	International Journal Of Technology Assessment In Health Care
Volume	26
Issue number	3
DOIs	https://doi.org/10.1017/S0266462310000358
Publication status	Published - 1 Jan 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Coronary heart disease
Cost-effectiveness analysis
General practice
Secondary prevention

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Gillespie, P, O'Shea, E, Murphy, A, Smith, S, Byrne, M, Byrne, M, Cupples, M
Gillespie, P. and O'Shea, E. and Murphy, A.W. and Byrne, M.C. and Byrne, M. and Smith, S.M. and Cupples, M.E.
Gillespie, P;O'Shea, E;Murphy, AW;Byrne, MC;Byrne, M;Smith, SM;Cupples, ME

Access to Document

10.1017/S0266462310000358

Cite this

@article{7a2494de91694b90a71e71fcba2fb1dc,

title = "The cost effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease",

abstract = "Objectives: The Secondary Prevention of Heart disEase in geneRal practicE (SPHERE) trial has recently reported. This study examines the cost-effectiveness of the SPHERE intervention in both healthcare systems on the island of Ireland. Methods: Incremental cost-effectiveness analysis. A probabilistic model was developed to combine within-trial and beyond-trial impacts of treatment to estimate the lifetime costs and benefits of two secondary prevention strategies: Intervention - tailored practice and patient care plans; and Control - standardized usual care. Results: The intervention strategy resulted in mean cost savings per patient of 512.77 (95 percent confidence interval [CI], 1086.46-91.98) and an increase in mean quality-adjusted life-years (QALYs) per patient of 0.0051 (95 percent CI, 0.0101-0.0200), when compared with the control strategy. The probability of the intervention being cost-effective was 94 percent if decision makers are willing to pay €45,000 per additional QALY. Conclusions: Decision makers in both settings must determine whether the level of evidence presented is sufficient to justify the adoption of the SPHERE intervention in clinical practice.",

keywords = "Coronary heart disease, Cost-effectiveness analysis, General practice, Secondary prevention",

author = "Patrick Gillespie and Molly Byrne",

year = "2010",

month = jan,

day = "1",

doi = "10.1017/S0266462310000358",

language = "English (Ireland)",

volume = "26",

pages = "263--271",

journal = "International Journal Of Technology Assessment In Health Care",

number = "3",

}

TY - JOUR

T1 - The cost effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease

AU - Gillespie, Patrick

AU - Byrne, Molly

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objectives: The Secondary Prevention of Heart disEase in geneRal practicE (SPHERE) trial has recently reported. This study examines the cost-effectiveness of the SPHERE intervention in both healthcare systems on the island of Ireland. Methods: Incremental cost-effectiveness analysis. A probabilistic model was developed to combine within-trial and beyond-trial impacts of treatment to estimate the lifetime costs and benefits of two secondary prevention strategies: Intervention - tailored practice and patient care plans; and Control - standardized usual care. Results: The intervention strategy resulted in mean cost savings per patient of 512.77 (95 percent confidence interval [CI], 1086.46-91.98) and an increase in mean quality-adjusted life-years (QALYs) per patient of 0.0051 (95 percent CI, 0.0101-0.0200), when compared with the control strategy. The probability of the intervention being cost-effective was 94 percent if decision makers are willing to pay €45,000 per additional QALY. Conclusions: Decision makers in both settings must determine whether the level of evidence presented is sufficient to justify the adoption of the SPHERE intervention in clinical practice.

AB - Objectives: The Secondary Prevention of Heart disEase in geneRal practicE (SPHERE) trial has recently reported. This study examines the cost-effectiveness of the SPHERE intervention in both healthcare systems on the island of Ireland. Methods: Incremental cost-effectiveness analysis. A probabilistic model was developed to combine within-trial and beyond-trial impacts of treatment to estimate the lifetime costs and benefits of two secondary prevention strategies: Intervention - tailored practice and patient care plans; and Control - standardized usual care. Results: The intervention strategy resulted in mean cost savings per patient of 512.77 (95 percent confidence interval [CI], 1086.46-91.98) and an increase in mean quality-adjusted life-years (QALYs) per patient of 0.0051 (95 percent CI, 0.0101-0.0200), when compared with the control strategy. The probability of the intervention being cost-effective was 94 percent if decision makers are willing to pay €45,000 per additional QALY. Conclusions: Decision makers in both settings must determine whether the level of evidence presented is sufficient to justify the adoption of the SPHERE intervention in clinical practice.

KW - Coronary heart disease

KW - Cost-effectiveness analysis

KW - General practice

KW - Secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=78049444223&partnerID=8YFLogxK

U2 - 10.1017/S0266462310000358

DO - 10.1017/S0266462310000358

M3 - Article

VL - 26

SP - 263

EP - 271

JO - International Journal Of Technology Assessment In Health Care

JF - International Journal Of Technology Assessment In Health Care

IS - 3

ER -

The cost effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease

Abstract

UN SDGs

Keywords

Authors (Note for portal: view the doc link for the full list of authors)

Access to Document

Other files and links

Fingerprint

Cite this